0 0 0
Dieser Online-Shop verwendet Cookies für ein optimales Einkaufserlebnis. Dabei werden beispielsweise die Session-Informationen oder die Spracheinstellung auf Ihrem Rechner gespeichert. Ohne Cookies ist der Funktionsumfang des Online-Shops eingeschränkt. Sind Sie damit nicht einverstanden, klicken Sie bitte hier.

Moriya Pathology of Female Cancers

Precursor and Early-Stage Breast Ovarian and Uterine Carcinomas

ISBN: 978-981-10-8605-2

Erscheinungsdatum: August 2018

Einband: Hardcover

Seitenzahl: 91 p.

Illustrationen: 120 ill.

Verlag: Springer

Lieferzeit ab Ihrer Bestellung: 2-14 Tage je nach Lieferbarkeit und Verlag

Beschreibung

  • Elaborates on the pathological points of view about carcinomas of female-specific organs
  • Broadens understanding of new concepts in the pathology of female cancers
  • Provides thorough explanations of the molecular and clinicopathologic basis of female cancers
This book focuses on precursor lesions, borderline lesions, and early carcinomas of female-specific organs from the standpoint of pathology. In 2012, WHO Classification of Tumours of the Breast was revised and subsequently, in 2014, the WHO Classification of Tumours of Female Reproductive Organs was revised. In these latest versions, several new concepts are addressed that were not described in the previous editions, and many of them are related to the awareness of the specific pathogenesis of tumors in female patients. Although some of these issues are still controversial, several paradigm shifts should be understood by medical scientists. Thus researchers, diagnostic pathologists, and clinicians must share current information about what is taking place in the field and what the next issue to resolve is.

This volume greatly broadens the reader’s understanding of the new concepts and paradigm shifts, as it includes information on how to diagnose and make differential diagnoses on a practical basis and also provides a thorough explanation of the molecular–clinicopathologic basis of the new concepts. The book thus benefits gynecologists, breast surgeons, gynecologic–medical oncologists, and cytotechnologists.